anergiX RA

a complex of solubilized HLA DRB1-0401 together with a specific peptide from the human cartilage glycoprotein HCgp39, for the potential treatment of rheumatoid arthritis

Also Known As:

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Prokaeva, T: 1 article (09/2000)

Related Diseases

1.	Rheumatic Diseases (Rheumatism) 09/01/2000 - "Researchers at Organon identified the central component in AnergiX.RA; results from preclinical studies identifying this target protein were published in June 1997 in Arthritis & Rheumatism. "
2.	Arthritis (Polyarthritis) 09/01/2000 - "Researchers at Organon identified the central component in AnergiX.RA; results from preclinical studies identifying this target protein were published in June 1997 in Arthritis & Rheumatism. "
3.	Rheumatoid Arthritis 09/01/2000 - "Corixa (formerly Anergen), in collaboration with Organon, is developing AnergiX.RA, a complex of solubilized HLA DRB1-0401(a) together with a specific peptide from the human cartilage glycoprotein HCgp39, for the potential treatment of rheumatoid arthritis (RA) [307156]. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Peptides (Polypeptides)
3.	Glycoproteins (Glycoprotein)